TRCT
GOSS icon

Tower Research Capital (TRC)’s Gossamer Bio GOSS Stock Holding History

Tower Research Capital (TRC)’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.9K Buy
36,342
+19,107
+111% +$30K ﹤0.01% 3814
2025
Q4 		$53.4K Buy
17,235
+4,287
+33% +$12.2K ﹤0.01% 2370
2025
Q3 		$34.1K Buy
12,948
+10,699
+476% +$23.6K ﹤0.01% 2831
2025
Q2 		$2.77K Sell
2,249
-2,885
-56% -$3.15K ﹤0.01% 4596
2025
Q1 		$5.65K Buy
+5,134
New +$5.93K ﹤0.01% 4100
2024
Q4 		– Sell
-4,456
Closed -$4.39K – 5801
2024
Q3 		$4.39K Sell
4,456
-14,240
-76% -$13.7K ﹤0.01% 4560
2024
Q2 		$16.8K Buy
18,696
+1,398
+8% +$1.05K ﹤0.01% 3853
2024
Q1 		$20.4K Buy
17,298
+12,496
+260% +$13.8K ﹤0.01% 2986
2023
Q4 		$4.38K Sell
4,802
-25,354
-84% -$18.7K ﹤0.01% 4961
2023
Q3 		$25.1K Buy
30,156
+8,313
+38% +$9.58K ﹤0.01% 3167
2023
Q2 		$26.2K Sell
21,843
-70,593
-76% -$87.9K ﹤0.01% 3145
2023
Q1 		$116K Buy
92,436
+23,548
+34% +$45.1K ﹤0.01% 1729
2022
Q4 		$149K Buy
68,888
+53,100
+336% +$437K 0.01% 1518
2022
Q3 		$189K Buy
15,788
+12,852
+438% +$160K ﹤0.01% 1989
2022
Q2 		$25K Sell
2,936
-5,315
-64% -$41.2K ﹤0.01% 3554
2022
Q1 		$71K Buy
8,251
+5,400
+189% +$52.1K ﹤0.01% 2447
2021
Q4 		$32K Sell
2,851
-4,647
-62% -$55.2K ﹤0.01% 3167
2021
Q3 		$94K Sell
7,498
-1,434
-16% -$13.2K ﹤0.01% 2450
2021
Q2 		$72K Buy
8,932
+6,662
+293% +$57.8K ﹤0.01% 2705
2021
Q1 		$21K Sell
2,270
-1,688
-43% -$17K ﹤0.01% 3840
2020
Q4 		$38K Buy
3,958
+1,726
+77% +$17K ﹤0.01% 3371
2020
Q3 		$28K Sell
2,232
-5,587
-71% -$74.1K ﹤0.01% 3750
2020
Q2 		$102K Buy
+7,819
New +$98.3K ﹤0.01% 2438
2020
Q1 		– Sell
-1,708
Closed -$27K – 3368
2019
Q4 		$27K Sell
1,708
-12,554
-88% -$253K ﹤0.01% 1735
2019
Q3 		$239K Buy
+14,262
New +$284K 0.02% 913
2019
Q2 		– Sell
-118
Closed -$3K – 3906
2019
Q1 		$3K Buy
+118
New +$2.46K ﹤0.01% 3286

Other funds holding GOSS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Tower Research Capital (TRC)'s GOSS Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Gossamer Bio (GOSS) stake by 111% in Q1 2026, buying an estimated $30K and bringing the position to 36,342 shares worth $11.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3814.

Tower Research Capital (TRC) first reported a position in GOSS in Q1 2019 and has held it in 26 quarters since. The position peaked at $239K in Q3 2019. 184 funds tracked by Wall St. Rank hold GOSS as of Q1 2026.

  • Tower Research Capital (TRC) held 36,342 shares of Gossamer Bio worth $11.9K as of Q1 2026.
  • Tower Research Capital (TRC) bought 19,107 Gossamer Bio shares in Q1 2026, an estimated $30K.
  • Gossamer Bio made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3814 holding.
  • Tower Research Capital (TRC) first reported a position in Gossamer Bio in Q1 2019 and has held it in 26 quarters since.
  • Tower Research Capital (TRC)'s Gossamer Bio position peaked at $239K in Q3 2019.
  • 184 funds tracked by Wall St. Rank held Gossamer Bio as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.